Last reviewed 2026-04-19 · How we verify

Mogamulizumab-Kpkc

Mogamulizumab-Kpkc is a Chemokine Receptor Type 4 Interaction [EPC] Small molecule drug developed by H. Lee Moffitt Cancer Center and Research Institute. It is currently in discontinued development for Mycosis fungoides, Peripheral T-cell lymphoma, Primary cutaneous T-cell lymphoma. Also known as: POTELIGEO.

12.1 Mechanism of Action Mogamulizumab-kpkc is a defucosylated, humanized IgG1 kappa monoclonal antibody that binds to CCR4, a G protein-coupled receptor for CC chemokines that is involved in the trafficking of lymphocytes to various organs. Non-clinical in vitro studies demonstrate mogamulizumab-kpkc binding targets a cell for antibody-dependent cellular cytotoxicity (ADCC) resulting in depletion of the target cells. CCR4 is expressed on the surface of some T-cell malignancies and is expressed on regulatory T-cells (Treg) and a subset of Th2 T-cells.

At a glance

Mechanism of action

1 INDICATIONS AND USAGE POTELIGEO is indicated for the treatment of adult patients with relapsed or refractory mycosis fungoides (MF) or Sézary syndrome (SS) after at least one prior systemic therapy. POTELIGEO is a CC chemokine receptor type 4 (CCR4)-directed monoclonal antibody indicated for the treatment of adult patients with relapsed or refractory mycosis fungoides or Sézary syndrome after at least one prior systemic therapy ( 1 ).

Approved indications

• Mycosis fungoides
• Peripheral T-cell lymphoma
• Primary cutaneous T-cell lymphoma

Common side effects

No common side effects on file.

Key clinical trials

• A Phase 1b/2 Study of Hu5F9-G4 (Magrolimab) in Combination With Mogamulizumab in Relapsed/Refractory Treated T-Cell Lymphoma (Phase 1)
• Phase 1 Study of Mogamulizumab (KW-0761) in Combination With MEDI4736 (Durvalumab) and Mogamulizumab in Combination With Tremelimumab in Subjects With Advanced Solid Tumors (Phase 1)
• A PHASE 1B STUDY OF PF-05082566 IN COMBINATION WITH MOGAMULIZUMAB (KW-0761) IN PATIENTS WITH ADVANCED SOLID TUMORS (Phase 1)
• Phase 1 Study of Recombinant Human IL-15 (rhIL-15) and Mogamulizumab for Patients With Refractory or Relapsed Adult T-Cell Leukemia and Mycosis Fungoides/Sezary Syndrome (Phase 1)
• A Phase II Study of Pembrolizumab and Mogamulizumab in Advanced-stage, Relapsed/Refractory Cutaneous T-cell Lymphomas (Phase 2)
• Open-Label, Phase 2 Study to Assess the Safety of Mogamulizumab Given Every 4 Weeks Following Induction in Participants With Relapsed/Refractory Cutaneous T-Cell Lymphoma (CTCL) (Phase 2)
• A Single-Arm, Open-Label, Pilot Study of Concurrent Phototherapy and POTELIGEO (Mogamulizumab-kpkc) in Early Stage Mycosis Fungoides (PLIGHT) (EARLY/Phase 1)
• Open-Label, Multi-Center, Phase 2 Study of Anti-CCR4 Monoclonal Antibody KW-0761 (Mogamulizumab) in Subjects With Previously Treated Peripheral T-cell Lymphoma (PTCL) (Phase 2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Mogamulizumab-Kpkc CI brief — competitive landscape report
• Mogamulizumab-Kpkc updates RSS · CI watch RSS
• H. Lee Moffitt Cancer Center and Research Institute portfolio CI

Frequently asked questions about Mogamulizumab-Kpkc

Related

• Drug class: All Chemokine Receptor Type 4 Interaction [EPC] drugs
• Target: All drugs targeting C-C chemokine receptor type 4
• Manufacturer: H. Lee Moffitt Cancer Center and Research Institute — full pipeline
• Therapeutic area: All drugs in Oncology
• Indication: Drugs for Mycosis fungoides
• Indication: Drugs for Peripheral T-cell lymphoma
• Indication: Drugs for Primary cutaneous T-cell lymphoma
• Also known as: POTELIGEO
• Compare: Mogamulizumab-Kpkc vs similar drugs
• Pricing: Mogamulizumab-Kpkc cost, discount & access